Efficacy and Cardiovascular Safety of Pegmolesatide in Patients with Anemia of Chronic Kidney Disease: Post hoc Analysis of Two Phase 3 Randomized Trials.

Kidney Dis (Basel) · 2026 · PMC13436941 · PMID 42553958

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a numerical trendno p-value reported

CV Safety In the entire study population, CV safety outcomes suggested a numerical trend favoring pegmolesatide in both DD-CKD and NDD-CKD patients.

also in 723 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.